-+ 0.00%
-+ 0.00%
-+ 0.00%

Telomir Pharmaceuticals wins FDA IND clearance for Telomir-Zn in triple-negative breast cancer

PUBT·04/30/2026 12:02:00
Listen to the news
Telomir Pharmaceuticals wins FDA IND clearance for Telomir-Zn in triple-negative breast cancer
  • Telomir Pharmaceuticals received FDA clearance of an IND for Telomir-Zn in advanced or metastatic triple-negative breast cancer.
  • Clearance supports launch of first-in-human Phase 1/2 trial TELO-001 in 1H 2026.
  • Study plans enrollment of about 76 patients, evaluating oral monotherapy safety, dosing, pharmacokinetics, biomarkers, preliminary efficacy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202604300800ACCESSWRNAPR_____1162409) on April 30, 2026, and is solely responsible for the information contained therein.